Back to discover
Disease
Panniculitis
Active therapeutic pipelineEmerging research
1
Publications
6
Clinical trials
2005
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Adipose tissue, inflammation, and cardiovascular disease.
Research2005-05-01Circulation research
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 2 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
- Q4 2026A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Q2 2044A Phase I Trial of Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Major developments
Major trial resultsHigh impact
Results posted2026-05-26
Upcoming trial readoutHigh impact
Results expected Q4 20262026-06-17
Clinical MilestonesViewHide
Results posted
Results expected
- 2026-06-25A Phase I Trial of Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)Results expected Q2 2044
- 2026-06-17A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic LymphomasResults expected Q4 2026
Activity timeline4
- 2029-03-01ClinicalPhase II Study of Brentuximab Vedotin in Combination With Pembrolizumab in Patients With Recurrent Systemic Peripheral T-Cell Lymphoma (PTCL)Withdrawn
- 2026-06-25ClinicalA Phase I Trial of Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)Results expected Q2 2044
- 2026-06-17ClinicalA Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic LymphomasResults expected Q4 2026
- 2026-05-26ClinicalA Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell LymphomasResults posted
Clinical trials
The current development programme across all trial phases.
Clinical programme
6
3
0
1
Recruiting
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Recent publications
Leading journals1
- Circulation research1
Leading researchers2
- Berg AH1
- Scherer PE1
Affiliations (unnormalised)1
- Albert Einstein College of Medicine1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
General term for inflammation of adipose tissue, usually of the skin, characterized by reddened subcutaneous nodules.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.